Company intelligence / Profile preview

Asarina Pharma AB

Ownership: Public · ASAP
Employees: ~7
Development stage: Phase 2

Overview

Asarina Pharma developed Sepranolone, which showed promising results in Phase IIa studies for Tourette Syndrome with a strong safety profile and no CNS off-target effects. The company completed a Phase IIb study for PMDD and was conducting Phase IIa studies for Menstrual Migraine before selling its assets to Relmada Therapeutics.

Therapeutic areas: Women's HealthPsychiatryNeurology
Modalities: Small molecules (Sepranolone)
Industry: Biotech

Drug pipeline

1 asset

sepranolone

Phase 2

Indications: Tourette syndrome, Obsessive-compulsive disorder, Premenstrual dysphoric disorder, Menstrual migraine

Partnerships

Relmada Therapeutics (acquired Sepranolone assets in February 2025)

Financials

Market cap: $0
Total revenue: $11.5M
Enterprise value: $54M

Beyond the preview

Go deeper on Asarina Pharma AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asarina Pharma AB.

Explore the full profile